Biopharmaceutical company specializing on developing second generation therapies to better lives of patients with severe brain injuries Bright Minds Biosciences Inc. (CNSX: DRUG) (OTCQB:BMBIF) announced that its shares will begin trading on the OTCQB venture market starting from May 17.
Shares of the company will be trading under the ticker symbol ‘BMBIF’. The company’s chief executive Ian McDonald expressed how delighted they are as a company as this listing will indeed increase the company’s liquidity and diversify shareholders’ equity.
“Acceptance to the OTCQB is an important step in our company’s growth trajectory, and we are excited for the opportunity to build visibility, increase liquidity and diversify our shareholder base. This additional capital markets exposure will support our efforts to design and develop next-generation therapeutics to address difficult-to-treat indications across mental health disorders and pain management. We are also in the process of listing on a tier-one U.S.-based exchange,” said the CEO.
Bright Minds will continue trading on Canadian Stock Exchange (CSE) under the ticker symbol ‘DRUG’. The OTCQB is a capital market operated by OTC Markets Group Inc. and it focuses on early stage and developing United States and International companies.
